

Sun Pharma Advanced Research Company Ltd.
17/B, Mahal Industrial Estate,
Mahakali Caves Road,
Andheri (East), Mumbai 400 093 India
Tel.: (91-22) 6645 5645
Fax.: (91-22) 6645 5685



FOR IMMEDIATE RELEASE

SPARC receives US FDA response on Levetiracetam NDA

May 4, 2013, Mumbai: Sun Pharma Advanced Research Company Ltd. (SPARC, NSE: SPARC, BSE: 532872) announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) on its New Drug Application (NDA) for Levetiracetam Extended-release Tablets, 1000mg and 1500mg, an anti-epileptic product. A Complete Response Letter is a communication from the FDA to companies that an NDA cannot be approved in its present form.

In the Complete Response Letter, the FDA specified that the clinical data submitted by SPARC establishes bioequivalence in the fasted state. However, the FDA has raised certain queries on the Pharmacokinetic data in the fed state. SPARC is evaluating the contents of the letter and plans further discussions with the FDA.

About SPARC

Sun Pharma Advanced Research Company Ltd is an international pharmaceutical company engaged in research and development of drugs and delivery systems. More information about the company can be found at www.sunpharma.in.

Contact

Nimish Desai
Tel +91 22 6645 5645, Ext 717
Tel Direct +91 22 66455717
Mobile +91 98203 30182
E mail nimish.desai@sunpharma.com

Mira Desai
Tel +91 22 6645 5645, Ext 606
Tel Direct +91 22 66455606
Mobile +91 98219 23797
E mail miradesai@sunpharma.com